Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe NIH banner announcing website updates and the temporary shift from “Artificial Intelligence” to “Super Intelligence” terminology was removed.SummaryDifference1%

- Check22 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2, while the study page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide notice announces an NIH transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The study record itself is not displayed.SummaryDifference1%

- Check36 days agoChange DetectedThe record presents details of a Phase 2 study of sacituzumab govitecan for metastatic castration-resistant prostate cancer, including its treatment plan, eligibility criteria, outcome measures, and study locations. It also includes the study’s current status and record history.SummaryDifference50%

- Check43 days agoChange DetectedThe footer displays site revision v3.7.1 instead of v3.7.0. The study page continues to show a 403 error.SummaryDifference0.2%

Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.